CC-90001

Phase 2Small molecule

Bristol-Myers Squibb

CC-90001 is one of 110 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

109

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary FibrosisActive, not recruiting

Non-Alcoholic SteatohepatitisActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Pulmonary FibrosisPhase 1

Active, not recruiting

Non-Alcoholic SteatohepatitisPhase 2

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

179 competitors in Idiopathic Pulmonary Fibrosis

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Phase 3

2 2

Thalomid

Bristol-Myers Squibb

Phase 3

2 3

Letairis

Gilead

Phase 3

1 4

Prevacid

Takeda

Phase 3

1 5

Gleevec

Novartis

Phase 3

1 6

MS Contin

Jascayd

1 8

Coumadin

AAbbott

Phase 3

1 9

Minocin

TTriax

Phase 3

1 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tics2 trials

First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02110420·96 enrolled

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03958864·60 enrolled

Adult Subject1 trial

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03363815·56 enrolled

Pulmonary Fibrosis1 trial

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02510937·16 enrolled

Non-Alcoholic Steatohepatitis1 trial

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT04048876·56 enrolled

Idiopathic Pulmonary Fibrosis1 trial

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03142191·138 enrolled

3 more indications

Metabolism1 trial

Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04655898·8 enrolled

Hepatic Impairment1 trial

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03742882·40 enrolled

Unspecified1 trial

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02321644·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for CC-90001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-90001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-90001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

CC-90001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tics2 trials

Adult Subject1 trial

Pulmonary Fibrosis1 trial

Non-Alcoholic Steatohepatitis1 trial

Idiopathic Pulmonary Fibrosis1 trial

Metabolism1 trial

Hepatic Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News